Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease

Transl Psychiatry. 2020 Mar 2;10(1):81. doi: 10.1038/s41398-020-0757-2.

Balmiki Ray¹, Bryan Maloney^{1

2}, Kumar Sambamurti³, Hanuma K Karnati⁴, Peter T Nelson⁵, Nigel H Greig⁴, Debomoy K Lahiri^{6

7

8}

¹ Department of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
² Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
³ Department of Neurosciences, Medical University of South Carolina, Charleston, 29425 SC, USA.
⁴ National Institute on Aging, Drug Design and Development Section, Bethesda, MD, 20892, USA.
⁵ Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.
⁶ Department of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. dlahiri@iupui.edu.
⁷ Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. dlahiri@iupui.edu.
⁸ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. dlahiri@iupui.edu.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.